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Primary biliary cholangitis: an update on treatment 
 
Gerri Mortimore, Senior Lecturer at the University of Derby, provides an updated clinical review on 
therapeutic options in light of the latest guidance 
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is a chronic but 
progressive disease that, over many years, causes damage to bile ducts, leading to cholestasis and, in 
some patients, cirrhosis. The rate at which PBC progresses varies from person to person, but significant 
damage takes decades to occur. It predominately affects women aged 40–60 years with a female to 
male ratio of 9:1, but can affect anyone from the age of 20. There is no cure for PBC other than liver 
transplant, but medications can be given to slow down disease progression and for the treatment of 
symptoms. Health professionals should monitor for complications, including the development of 
osteoporosis, vitamin deficiencies and liver cirrhosis, which carries the associated complications of 
portal hypertension, varices and ascites 
Ursodeoxycholic acid (UDCA) The primary drug of choice for the treatment of PBC is ursodeoxycholic 
acid (UDCA), due to its anticholestatic effects that can slow disease progression. However, it is more 
effective if given in the early stages of PBC. UCDA is sold as Ursofalk (Dr Falk, Bourne End) and Ursodiol 
(Watson Pharma Private, Salcette Goa, India). The usual dose is between 13–15 mg/kg daily. This 
provides a 90% improvement in ALP and GGT within the first 9–12 months (Lindor et al, 2009). The 
degree of biochemical response correlates with long-term prognosis; patients with ALP < 3x ULN, AST 
< 2x ULN and bilirubin ≤ x1 mg/dl after 1 year of UDCA had a 90% 
transplant-free survival (Poupon, 2010). However, a systematic review by Gong et al (2007) revealed 
that UDCA does not reduce mortality in PBC patients. UDCA has been shown to be safe to take. 
However, a small number of patients are intolerant of the drug, as it can cause gastrointestinal upset, 
mainly in the form of diarrhoea, but also less commonly nausea and vomiting and thinning of the hair 
(Lindor, 2009). If patients do complain of gastrointestinal upset, then UDCA can be commenced at 
smaller doses, and then increased if tolerated until the patient’s maximum tolerated level is reached. 
The use of obeticholic acid, sold as Ocaliva (Intercept, New York), has been approved for PBC in 
guidelines from EASL (Hirschfield et al, 2017). Monotherapy is suggested for patients who are 
intolerant to UDCA, while dual therapy is recommended for those with an inadequate response to 
UDCA. 
Obeticholic acid (OBA) Since the original publication of the article this update is based on, new PBC 
treatment and management guidelines have been published by the British Society of 
Gastroenterology (BSG) in conjunction with UK PBC (Hirschfield et al, 2018). These UK guidelines 
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acknowledge recommendations produced by the European Association for the Study of the Liver 
(EASL) in 2017. One of the major changes in the management of PBC was the launch of a second line 
drug treatment option called obeticholic acid (OCA), which has been licensed and endorsed by the 
National Institute for Health and Care Excellence (NICE) (2017a), and acts by helping to reduce bile 
acid production and increase the flow of bile acids out of the liver. Patients who have failed to respond 
to UDCA, or are intolerant of the drug, can now have this medication prescribed either as dual therapy 
with UDCA, or as monotherapy. For an adult, the recommended prescribed dose is 5 mg once daily 
(OD) for  6  months, increasing to 10 mg OD if required and tolerated. However, this drug has known 
common side effects (Table 1), as well as the risk of serious liver injury in patients with moderate or 
severe hepatic impairment. The Medicines and Healthcare products Regulatory Agency, (MHRA) 
acknowledges this severe risk, recommending dose adjustment according to liver function tests, which 
is also the recommendation in the UK guidelines (Hirschfield et al, 2018). All patients defined as 
suboptimal responders to first line treatment with UDCA should be referred to specialist liver centres 
for assessment and suitability for second line treatment and initiation of close monitoring of liver 
function tests and side effects, such as itching, which can be a symptom of PBC and side effect of OCA. 
NICE (2017a) and BSG/UKPBC guidelines (Hirschfield et al, 2018) recommend that clinicians should 
monitor the response of OCA after 12 months of treatment and only continue with the treatment if 
there is clinical benefit. Compared to UDCA, OCA is expensive costing approximately £2384 per pack 
of 30 tablets. The cost does vary according to local procurement costs and patient access schemes 
with the Department of Health. NICE acknowledged the cost effectiveness of dual therapy with UDCA 
increased both life expectancy and quality of life (NICE 2017b). Transplantation Patients should be 
considered for transplantation either if their total bilirubin approaches 100 or if they score highly on 
a test used by clinicians to indicate the severity of liver disease. This would include a Model for End-
stage Liver Disease (MELD) score greater than 12 or a United Kingdom model for End-stage Liver 
Disease (UKELD) score greater than 49. Patients with intractable pruritus can also be offered liver 
transplantation. Unfortunately, PBC recurs in around 20% of transplanted patients with associated 
symptoms of pruritis and fatigue (Poupon, 2010), although transplanted patients can still complain of 
fatigue (Hirschfield et al, 2017)   
 
Box 1. Common side effects of obeticholic acid (OBA) • Constipation • Dizziness • Palpitations • 
Peripheral oedema • Fatigue • Increased temperature • Skin reactions (including pruritis) • 
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